- Home
- SABA vs AQST Comparison
SABA vs AQST Comparison
Compare SABA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABA
- AQST
- Stock Information
- Founded
- SABA 1988
- AQST 2004
- Country
- SABA United States
- AQST United States
- Employees
- SABA N/A
- AQST N/A
- Industry
- SABA
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SABA
- AQST Health Care
- Exchange
- SABA Nasdaq
- AQST Nasdaq
- Market Cap
- SABA 247.3M
- AQST 274.4M
- IPO Year
- SABA N/A
- AQST 2018
- Fundamental
- Price
- SABA $8.78
- AQST $3.02
- Analyst Decision
- SABA
- AQST Strong Buy
- Analyst Count
- SABA 0
- AQST 7
- Target Price
- SABA N/A
- AQST $10.57
- AVG Volume (30 Days)
- SABA 290.0K
- AQST 1.4M
- Earning Date
- SABA 01-01-0001
- AQST 03-05-2025
- Dividend Yield
- SABA 12.91%
- AQST N/A
- EPS Growth
- SABA N/A
- AQST N/A
- EPS
- SABA N/A
- AQST N/A
- Revenue
- SABA N/A
- AQST $57,561,000.00
- Revenue This Year
- SABA N/A
- AQST N/A
- Revenue Next Year
- SABA N/A
- AQST $35.72
- P/E Ratio
- SABA N/A
- AQST N/A
- Revenue Growth
- SABA N/A
- AQST 13.79
- 52 Week Low
- SABA $3.64
- AQST $2.24
- 52 Week High
- SABA $4.42
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- SABA 43.38
- AQST 50.92
- Support Level
- SABA $8.62
- AQST $3.05
- Resistance Level
- SABA $8.98
- AQST $3.24
- Average True Range (ATR)
- SABA 0.12
- AQST 0.20
- MACD
- SABA 0.01
- AQST 0.04
- Stochastic Oscillator
- SABA 62.50
- AQST 57.47
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.